Onconic Therapeutics (476060) Fundamentals 2026 — P/E 24.6x, Revenue Analysis | SniperIQ
Onconic Therapeutics (476060) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩121.3B, trading at ₩10960.00 on the KOE. This SniperIQ fundamentals page covers Onconic Therapeutics's valuation (P/E 24.6x, P/B 6.2x), profitability (net margin 30.2%), revenue (₩53.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Onconic Therapeutics's market cap?
Onconic Therapeutics (476060) has a market capitalization of approximately ₩121.3B, trading at ₩10960.00 on the KOE. Market cap moves with the live share price.
What is Onconic Therapeutics's P/E ratio?
Onconic Therapeutics's trailing twelve-month P/E ratio is 24.6x, with a price-to-book (P/B) of 6.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Onconic Therapeutics?
Onconic Therapeutics runs a net profit margin of 30.2%, a gross margin of 65.2%, and an operating margin of 23.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Onconic Therapeutics generate?
Onconic Therapeutics reported revenue of ₩53.4B for fiscal year 2025, with net income of ₩15.8B and earnings per share (EPS) of 358.67. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Onconic Therapeutics pay a dividend?
Onconic Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Onconic Therapeutics financially healthy?
Onconic Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 9.48x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Onconic Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Onconic Therapeutics (476060) the key facts are: market cap ₩121.3B, P/E 24.6x, revenue ₩53.4B, 52-week range 5662.5-28900. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Onconic Therapeutics's full fundamentals live
Get Onconic Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.